


Appendix 15b: Clinical evidence forest plots (psychosocial interventions)

Psychosocial interventions.....	2
Cognitive behavioural therapy	2
Psychodynamic interventions	8
Contingency management.....	12
Contingency management - number of urinalyses	28
Family interventions.....	31
Opioid agonist plus cognitive behavioural therapy	39
Opioid agonist plus contingency management.....	47
Naltrexone plus psychosocial interventions	57
Case management.....	64
Multimodal interventions	70
Vocational interventions	78


Psychosocial interventions

Cognitive behavioural therapy


Review: DMP TG3 - 01: CBT
 Comparison: 01 CBT (RP) versus waitlist for cannabis
 Outcome: 02 Abstinence for people who misuse cannabis




Review: DMP TG3 - 01: CBT
 Comparison: 02 Group CBT (RP) versus group therapy for cannabis
 Outcome: 01 Abstinence: negative urinalysis for cannabis




Review: DMP TG3 - 01: CBT
 Comparison: 02 Group CBT (RP) versus group therapy for cannabis
 Outcome: 02 Drug use: cannabis, self-reported days per month (change from baseline, people who misuse cannabis)




Review: DMP TG3 - 01: CBT
 Comparison: 04 CBT versus standard care for cocaine
 Outcome: 01 Abstinence for people who misuse cocaine - self report




Review: DMP TG3 - 01: CBT
 Comparison: 06 CBT (RP) versus standard care for cocaine
 Outcome: 03 Abstinence: cocaine, self-report (people who misuse cocaine)



Review: DMP TG3 - 01: CBT
 Comparison: 06 CBT (RP) versus standard care for cocaine
 Outcome: 04 Abstinence: cocaine, self-reported % days in past 3 months (people who misuse cocaine)




Review: DMP TG3 - 01: CBT
 Comparison: 06 CBT (RP) versus standard care for cocaine
 Outcome: 05 Drug use: self-reported days in past 90 days (people who misuse drugs and alcohol)




Psychodynamic interventions


Review: DMP TG3 - 03: Psychodynamic interventions
 Comparison: 01 MMT + Psychodynamic vs Control
 Outcome: 04 Drug use: completers analysis (end of treatment and follow up)




Review: DMP TG3 - 03: Psychodynamic interventions
 Comparison: 02 MMT+Psychodynamic vs MMT+CBT
 Outcome: 01 Drug use: completers analysis (end of treatment and follow up)




Review: DMP TG3 - 03: Psychodynamic interventions
 Comparison: 03 Psychodynamic vs CBT for cocaine dependence
 Outcome: 01 Abstinence for 2 months




Review: DMP TG3 - 03: Psychodynamic interventions
 Comparison: 03 Psychodynamic vs CBT for cocaine dependence
 Outcome: 02 Relapse - cocaine use (12 month follow up)



Review: DMP TG3 - 03: Psychodynamic interventions
 Comparison: 05 Psychodynamic vs Control for cocaine dependence
 Outcome: 01 Abstinence for 2 months




Review: DMP TG3 - 03: Psychodynamic interventions
 Comparison: 05 Psychodynamic vs Control for cocaine dependence
 Outcome: 02 Relapse (12 months)




Contingency management


Review: DMP TG3 - 02: CM
 Comparison: 01 CM versus control: cocaine or opiates
 Outcome: 02 Abstinence from cocaine (during treatment)




Review: DMP TG3 - 02: CM
 Comparison: 01 CM versus control: cocaine or opiates
 Outcome: 03 Abstinence from cocaine (follow up)




Review: DMP TG3 - 02: CM
 Comparison: 01 CM versus control: cocaine or opiates
 Outcome: 04 Never abstinent for cocaine




Review: DMP TG3 - 02: CM
 Comparison: 01 CM versus control: cocaine or opiates
 Outcome: 06 Abstinence from cocaine: minimum duration (during treatment)




Review: DMP TG3 - 02: CM
 Comparison: 01 CM versus control: cocaine or opiates
 Outcome: 07 Abstinence from opiates and cocaine: minimum duration (during treatment)




Review: DMP TG3 - 02: CM
 Comparison: 02 CM versus control: metamphetamine
 Outcome: 08 Abstinence for methamphetamine: minimum duration (during treatment)




Review: DMP TG3 - 02: CM
 Comparison: 02 CM versus control: methamphetamine
 Outcome: 09 Continuous weeks of abstinence for methamphetamine




Review: DMP TG3 - 02: CM
 Comparison: 03 CM versus control: cannabis
 Outcome: 10 Abstinence from cannabis: minimum duration (during treatment)




Review: DMP TG3 - 02: CM
 Comparison: 03 CM versus control: cannabis
 Outcome: 12 Abstinence from cannabis (during treatment)




Review: DMP TG3 - 02: CM
 Comparison: 03 CM versus control: cannabis
 Outcome: 13 Abstinence from cannabis: self-report (followup)




Review: DMP TG3 - 02: CM
 Comparison: 04 CM versus CBT: stimulants
 Outcome: 01 Abstinence from stimulants: minimum duration (during treatment)




Review: DMP TG3 - 02: CM
 Comparison: 04 CM versus CBT: stimulants
 Outcome: 02 Abstinence from stimulants (during treatment)




Review: DMP TG3 - 02: CM
 Comparison: 04 CM versus CBT: stimulants
 Outcome: 03 Abstinence from stimulants: negative urinalysis (post-treatment)




Review: DMP TG3 - 02: CM
 Comparison: 04 CM versus CBT: stimulants
 Outcome: 04 Methamphetamine use: days in past month (post-treatment)




Review: DMP TG3 - 02: CM
 Comparison: 05 CM versus CBT: cannabis
 Outcome: 05 Abstinence from cannabis: minimum duration (during treatment)




Review: DMP TG3 - 02: CM
 Comparison: 05 CM versus CBT: cannabis
 Outcome: 06 Abstinence from cannabis (during treatment)



Review: DMP TG3 - 02: CM
 Comparison: 05 CM versus CBT: cannabis
 Outcome: 07 Abstinence from cannabis (post-treatment and follow up)




Review: DMP TG3 - 02: CM
 Comparison: 05 CM versus CBT: cannabis
 Outcome: 08 Cannabis use: days in past month (post-treatment)




Contingency management - number of urinalyses


Review: DMP TG3 - 07: CM by number of urinalyses
 Comparison: 01 CM vs control for cocaine (for 1/2 vs 3 urines a week)
 Outcome: 01 Abstinence for stimulants



Review: DMP TG3 - 07: CM by number of urinalyses
 Comparison: 02 MMT + CM (1, 2 or 3 urines a week)
 Outcome: 01 Achieved a minimum period of abstinence




Review: DMP TG3 - 07: CM by number of urinalyses
 Comparison: 02 MMT + CM (1, 2 or 3 urines a week)
 Outcome: 02 Abstinence at 6 month follow up




Family interventions


Review: DMP TG3 - 04: Family interventions
 Comparison: 01 Couple (BCT) versus CBT
 Outcome: 03 Abstinence: all drugs, -ve urinalysis




Review: DMP TG3 - 04: Family interventions
 Comparison: 02 Family intervention versus CBT: Young people
 Outcome: 02 Not clinically improved




Review: DMP TG3 - 04: Family interventions
 Comparison: 02 Family intervention versus CBT: Young people
 Outcome: 04 Drug use: Cannabis, self-report




Review: DMP TG3 - 04: Family interventions
 Comparison: 03 Family intervention versus psychoeducation: Young people
 Outcome: 03 Not clinically improved




Review: DMP TG3 - 04: Family interventions
 Comparison: 03 Family intervention versus psychoeducation: Young people
 Outcome: 04 Drug use: Cannabis, self-report




Review: DMP TG3 - 04: Family interventions
 Comparison: 05 Family intervention versus group therapy: Young people
 Outcome: 01 Not clinically improved



Review: DMP TG3 - 04: Family interventions
 Comparison: 05 Family intervention versus group therapy: Young people
 Outcome: 02 Abstinence: % -ve urinalysis




Review: DMP TG3 - 04: Family interventions
 Comparison: 08 (MMT + family intervention) versus MMT treatment-as-usual
 Outcome: 01 Drug use at endpoint (change from baseline)




Opioid agonist plus cognitive behavioural therapy


Review: DMP TG3 - 05: Opioid agonist + CBT
 Comparison: 01 MMT + CBT (RP) versus MMT + Control
 Outcome: 01 Abstinence: cocaine




Review: DMP TG3 - 05: Opioid agonist + CBT
 Comparison: 01 MMT + CBT (RP) versus MMT + Control
 Outcome: 02 Abstinence: primary drug




Review: DMP TG3 - 05: Opioid agonist + CBT
 Comparison: 01 MMT + CBT (RP) versus MMT + Control
 Outcome: 04 Drug use: primary drug (end of treatment change from baseline)




Review: DMP TG3 - 05: Opioid agonist + CBT
 Comparison: 01 MMT + CBT (RP) versus MMT + Control
 Outcome: 06 Primary drug use (change from baseline): follow up




Review: DMP TG3 - 05: Opioid agonist + CBT
 Comparison: 01 MMT + CBT (RP) versus MMT + Control
 Outcome: 07 Other drug use (end of treatment change from baseline)




Review: DMP TG3 - 05: Opioid agonist + CBT
 Comparison: 02 MMT + CBT (S) versus MMT + Control
 Outcome: 03 Drug use (endpoint change from baseline)




Review: DMP TG3 - 05: Opioid agonist + CBT
 Comparison: 04 MMT + CBT versus MMT + Other Treatment
 Outcome: 01 Abstinence



Review: DMP TG3 - 05: Opioid agonist + CBT
 Comparison: 04 MMT + CBT versus MMT + Other Treatment
 Outcome: 02 Minimum of 3 weeks abstinence




Review: DMP TG3 - 05: Opioid agonist + CBT
 Comparison: 04 MMT + CBT versus MMT + Other Treatment
 Outcome: 03 Drug use (end of treatment)




Opioid agonist plus contingency management


Review: DMP TG3 - 06: Opioid agonist + CM
 Comparison: 01 MMT + CM versus MMT + Control
 Outcome: 02 Abstinence: longest continuous period (ITT, during treatment)




Review: DMP TG3 - 06: Opioid agonist + CM
 Comparison: 01 MMT + CM versus MMT + Control
 Outcome: 03 Abstinence: longest continuous period (completers, during treatment)




Review: DMP TG3 - 06: Opioid agonist + CM
 Comparison: 01 MMT + CM versus MMT + Control
 Outcome: 04 Abstinence




Review: DMP TG3 - 06: Opioid agonist + CM
 Comparison: 01 MMT + CM versus MMT + Control
 Outcome: 05 Abstinence during follow up




Review: DMP TG3 - 06: Opioid agonist + CM
 Comparison: 01 MMT + CM versus MMT + Control
 Outcome: 06 continuous periods of abstinence (in weeks)




Review: DMP TG3 - 06: Opioid agonist + CM
 Comparison: 01 MMT + CM versus MMT + Control
 Outcome: 07 Proportion negative urine samples (change from baseline)




Review: DMP TG3 - 06: Opioid agonist + CM
 Comparison: 01 MMT + CM versus MMT + Control
 Outcome: 08 Drug use (change from baseline)




Review: DMP TG3 - 06: Opioid agonist + CM
 Comparison: 01 MMT + CM versus MMT + Control
 Outcome: 11 Never abstinent during study




Review: DMP TG3 - 06: Opioid agonist + CM
 Comparison: 02 Buprenorphine + CM versus buprenorphine + control
 Outcome: 01 Abstinence: achieved minimum period (during treatment)



Review: DMP TG3 - 06: Opioid agonist + CM
 Comparison: 02 Buprenorphine + CM versus buprenorphine + control
 Outcome: 02 Abstinence: longest continuous period (during treatment)




Review: DMP TG3 - 06: Opioid agonist + CM
 Comparison: 02 Buprenorphine + CM versus buprenorphine + control
 Outcome: 03 Abstinence: total number of weeks (during treatment)




Naltrexone plus psychosocial interventions


Review: DMP TG3 - 08: Naltrexone + psychosocial
 Comparison: 01 Naltrexone + CM versus naltrexone + control
 Outcome: 01 Naltrexone doses/days used (completers)




Review: DMP TG3 - 08: Naltrexone + psychosocial
 Comparison: 01 Naltrexone + CM versus naltrexone + control
 Outcome: 02 Longest continuous abstinence




Review: DMP TG3 - 08: Naltrexone + psychosocial
 Comparison: 01 Naltrexone + CM versus naltrexone + control
 Outcome: 03 Proportion days abstinent




Review: DMP TG3 - 08: Naltrexone + psychosocial
 Comparison: 02 Naltrexone + CBT versus naltrexone + control
 Outcome: 01 Naltrexone doses/days used (completers)




Review: DMP TG3 - 08: Naltrexone + psychosocial
 Comparison: 02 Naltrexone + CBT versus naltrexone + control
 Outcome: 02 Drug use: opiates




Review: DMP TG3 - 08: Naltrexone + psychosocial
 Comparison: 02 Naltrexone + CBT versus naltrexone + control
 Outcome: 03 Adverse events




Review: DMP TG3 - 08: Naltrexone + psychosocial
 Comparison: 02 Naltrexone + CBT versus naltrexone + control
 Outcome: 04 Abstinence: opiates




Review: DMP TG3 - 08: Naltrexone + psychosocial
 Comparison: 02 Naltrexone + CBT versus naltrexone + control
 Outcome: 05 Urinalysis: opiates




Review: DMP TG3 - 08: Naltrexone + psychosocial
 Comparison: 03 Naltrexone + behavioural FT versus naltrexone + control
 Outcome: 01 Naltrexone doses/days used (completers)



Review: DMP TG3 - 08: Naltrexone + psychosocial
 Comparison: 03 Naltrexone + behavioural FT versus naltrexone + control
 Outcome: 02 Proportion days abstinent




Review: DMP TG3 - 08: Naltrexone + psychosocial
 Comparison: 03 Naltrexone + behavioural FT versus naltrexone + control
 Outcome: 03 Longest continuous abstinence




Case management


Review: DMP TG3 - 09: Case management
 Comparison: 01 Intensive referral versus standard care, for out of treatment drug users
 Outcome: 02 Initiation: started any treatment prior to followup (ITT)




Review: DMP TG3 - 09: Case management
 Comparison: 02 Case management versus standard care, for out of treatment drug users
 Outcome: 02 Initiation: started any treatment prior to followup (ITT)




Review: DMP TG3 - 09: Case management
 Comparison: 02 Case management versus standard care, for out of treatment drug users
 Outcome: 04 Retention (ITT)



Review: DMP TG3 - 09: Case management
 Comparison: 02 Case management versus standard care, for out of treatment drug users
 Outcome: 05 Retention: time in treatment (endpoint, completers)




Review: DMP TG3 - 09: Case management
 Comparison: 02 Case management versus standard care, for out of treatment drug users
 Outcome: 07 Abstinence: -ve urine or hair analysis at follow-up (ITT)




Multimodal interventions


Review: DMP: Day treatment, intensive outpatient treatment and CM for work/housing
 Comparison: 02 Intensive outpatient treatment (10-12hr/wk) vs Standard outpatient treatment (~2hr/wk)
 Outcome: 01 Drug use: Self-reported days cocaine use in past 30 days (endpoint, completers)




Review: DMP TG3 - 10: Multimodal treatment programmes
 Comparison: 02 Intensive outpatient treatment (10-12hr/wk) vs Standard outpatient treatment (~2hr/wk)
 Outcome: 02 Abstinence: self-reported for cocaine (endpoint, ITT)




Review: DMP TG3 - 10: Multimodal treatment programmes
 Comparison: 02 Intensive outpatient treatment (10-12hr/wk) vs Standard outpatient treatment (~2hr/wk)
 Outcome: 03 Abstinence: achieved minimum duration, opiates (during treatment, ITT)




Review: DMP TG3 - 10: Multimodal treatment programmes
 Comparison: 02 Intensive outpatient treatment (10-12hr/wk) vs Standard outpatient treatment (~2hr/wk)
 Outcome: 04 Abstinence: achieved minimum duration, cocaine (during treatment, ITT)




Review: DMP TG3 - 10: Multimodal treatment programmes
 Comparison: 03 Day treatment (>18hr/wk) vs Standard outpatient treatment (~2hr/wk)
 Outcome: 01 Abstinence: -ve urinalysis (endpoint, ITT)




Review: DMP TG3 - 10: Multimodal treatment programmes
 Comparison: 03 Day treatment (>18hr/wk) vs Standard outpatient treatment (~2hr/wk)
 Outcome: 02 Abstinence: -ve urinalysis (6 months followup, ITT)




Review: DMP TG3 - 10: Multimodal treatment programmes
 Comparison: 03 Day treatment (>18hr/wk) vs Standard outpatient treatment (~2hr/wk)
 Outcome: 03 Abstinence: max number of consecutive -ve urines, cocaine (ITT)




Review: DMP TG3 - 10: Multimodal treatment programmes
 Comparison: 04 Intensive day treatment (60hr/wk) vs Day treatment (>18hr/wk)
 Outcome: 01 Abstinence: -ve urinalysis for cocaine (ITT)



Review: DMP TG3 - 10: Multimodal treatment programmes
 Comparison: 06 Intensive outpatient treatment with RBT (reinforcement-based therapy) vs Standard care
 Outcome: 01 Abstinence: % -ve urine samples (during treatment)



Review: DMP TG3 - 10: Multimodal treatment programmes
 Comparison: 06 Intensive outpatient treatment with RBT (reinforcement-based therapy) vs Standard care
 Outcome: 02 Abstinence: cocaine and opiates (during treatment)



Vocational interventions

Review: DMP TG3 - 11: Vocational interventions
 Comparison: 01 Pre-vocational counselling vs Control
 Outcome: 01 Employment

